The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

Cystic fibrosis, or CF, is a genetic disorder that ... Gunnar entered into a clinical trial in 2018 for a drug called Trikafta, which had received funding from the Boomer Esiason Foundation.

These trials showcased Alyftrek's comparable effectiveness to Trikafta in terms of lung function, measured by percent predicted forced expiratory volume, and demonstrated better performance in ...

Vertex is also evaluating Alyftrek in children with cystic fibrosis aged 2 to 5 years. In a separate press release, Vertex announced that the FDA has expanded Trikafta’s label to include an ...

“Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this ... and lower sweat chloride levels than TRIKAFTA, is another step in ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.